MARKET

CBAY

CBAY

CymaBay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.46
+0.20
+2.75%
Closed 16:00 11/27 EST
OPEN
7.21
PREV CLOSE
7.26
HIGH
7.50
LOW
7.17
VOLUME
523.41K
TURNOVER
--
52 WEEK HIGH
9.06
52 WEEK LOW
1.210
MARKET CAP
513.90M
P/E (TTM)
-7.9429
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CymaBay Therapeutics Announces Oral Late-Breaking Presentation Of Positive Results From The ENHANCE Global Phase 3 Study Evaluating Seladelpar For Primary Biliary Cholangitis At The Liver Meeting 2020
Seladelpar demonstrated anti-cholestatic, anti-inflammatory, and anti-pruritic activity through 3 and 6 months   Results highlight the potential for seladelpar to offer patients an efficacious and safe
Benzinga · 11/16 21:07
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 11/15 15:14
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13 12:40
CymaBay Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 5, 2020 / CymaBay Therapeutics, Inc.
ACCESSWIRE · 11/05 19:30
CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020
GlobeNewswire · 11/02 13:00
CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter and nine months ended September 30, 2020 and to provide a business update. Conference Call Details To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID 13709641. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.About CymaBay CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.  CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). For PBC, seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA.For additional information about CymaBay visit www.cymabay.com.Public Relations Contact:            Glenn Silver Lazar-FINN Partners (973) 818-8198 Glenn.silver@finnpartners.com Investor Relations Contact:Hans Vitzthum LifeSci Advisors, LLC (617) 430-7578 Hans@LifeSciAdvisors.com
GlobeNewswire · 10/30 21:32
DSS, PRVB, ATHM and QLYS among after-hours movers
Gainers: [[DSS]] +26.5%. [[PRVB]] +8.4%. [[GRTS]] +4.7%. [[LILA]] +3.4%. [[NVTA]] +3.1%.Losers: [[ATHM]] -6.9%. [[MRIN]] -5.2%. [[CRMD]] -3.8%. [[QLYS]] -3.3%. [[CBAY]] -2.3%.
Seekingalpha · 10/23 21:40
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22)
Benzinga · 10/23 11:26
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBAY. Analyze the recent business situations of CymaBay through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CBAY stock price target is 13.00 with a high estimate of 20.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 214
Institutional Holdings: 73.67M
% Owned: 106.94%
Shares Outstanding: 68.89M
TypeInstitutionsShares
Increased
27
11.46M
New
51
-2.76M
Decreased
42
9.96M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Robert Wills
President/Chief Executive Officer/Director/IR Contact Officer
Sujal Shah
Senior Vice President/Chief Scientific Officer
Charles McWherter
Chief Compliance Officer
Klara Dickinson
Vice President - Finance
Daniel Menold
Independent Director
Caroline Loewy
Independent Director
Paul Truex
Independent Director
Kurt von Emster
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. Its pipeline includes Seladelpar, MBX-2982 and CB-001. The Company’s lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The PPARd receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar focuses on treating certain diseases of the liver and a variety of disorders of lipid metabolism.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of CymaBay Therapeutics Inc stock information, including NASDAQ:CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBAY stock methods without spending real money on the virtual paper trading platform.